FibroBiologics (FBLG) Operating Leases (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Operating Leases of $1.1 million for Q2 2026, down 48.15% year-over-year from $2.1 million in Q2 2025, and down 28.43% on a QoQ basis from $1.5 million in Q1 2026.
FibroBiologics (FBLG) Operating Leases (2022 - 2026) Analysis & Trends
FibroBiologics has reported Operating Leases for 5 years, with the latest figure at $1.1 million in Q2 2026.
- Operating Leases for Q2 2026 came in at $1.1 million, down 48.15% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.1 million (down 48.15% YoY), and the FY2025 annual result was $1.7 million, up 73.17% from the prior year.
- Operating Leases declined to $1.1 million in Q2 2026, from $1.5 million in the prior quarter.
- Over five years, Operating Leases peaked at $2.1 million in Q2 2025 and troughed at $984000.0 in Q4 2024.
- A 5-year average of $1.5 million and a median of $1.5 million in 2024 frame the typical range for Operating Leases.
- The widest annual swing landed in 2025, when Operating Leases surged 79.81%; it then sank 48.15% in 2026.
- A 5-year view of Operating Leases shows it stood at $1.7 million in 2022, then slipped by 20.72% to $1.4 million in 2023, then decreased by 28.95% to $984000.0 in 2024, then jumped by 73.17% to $1.7 million in 2025, then plunged by 36.62% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $1.1 million in Q2 2026, $1.5 million in Q1 2026, and $1.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | FibroBiologics | 9.10 Mn | 9.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.08 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 1.70 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 865,000.00 |
| Dec 31, 2024 | 984,000.00 |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Dec 31, 2022 | 1.75 Mn |